(Total Views: 563)
Posted On: 10/16/2024 2:23:45 AM
Post# of 154132
This is our hint to a deal.
Just realized after this part :
*announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation
*and expect to start screening patients in December 2024.
Pay the sites. Training doctors & staff. Etc, etc..
But based on the # of patients, you also need to have that per patient cost banked away.
Repeat for early 2025 start of screening.
With these very near costs & maintaining a % of your cash, for on hand threshold levels, it all looks to me we are indeed very close to some great developments occurring.
Just realized after this part :
*announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation
*and expect to start screening patients in December 2024.
Pay the sites. Training doctors & staff. Etc, etc..
But based on the # of patients, you also need to have that per patient cost banked away.
Repeat for early 2025 start of screening.
With these very near costs & maintaining a % of your cash, for on hand threshold levels, it all looks to me we are indeed very close to some great developments occurring.
(5)
(1)
